Clinical Trial

Psychiatric Symptom Characteristics in Methamphetamine-Induced Psychosis With and Without Lifetime Cannabis Use

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This prospective cohort study aims to investigate factors associated with psychiatric symptom severity in participants diagnosed with methamphetamine-induced psychotic disorder (MP) with and without lifetime cannabis use (LCU). Participants hospitalized at Elazığ Mental Health and Diseases Hospital who meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for MP will be included. Participants will be divided into two groups based on the presence or absence of LCU. Psychiatric symptoms and clinical characteristics will be assessed weekly during an eight-week inpatient follow-up period using standardized psychometric instruments. The study aims to determine whether LCU influences the course and severity of psychiatric symptoms in MP and to identify environmental, individual, and familial factors associated with symptom progression.
Trial Details
NCT Number NCT07459270
Lead Sponsor Elazığ Mental Health and Diseases Hospital
Conditions Methamphetamine Induced Psychosis, Cannabis Use
Enrollment 90 participants
Start Date 2026-03-16
Primary Completion 2026-09-14 (estimated)
Study Completion 2026-11-23 (estimated)
Updated on ClinicalTrials.gov 2026-03-09